Last updated: February 22, 2026
What is the drug associated with NDC 00054-0021?
NDC 00054-0021 corresponds to Rituximab, marketed under the brand name Rituxan. It is a monoclonal antibody used primarily to treat hematologic malignancies, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and autoimmune diseases like rheumatoid arthritis.
What is the current market landscape for Rituximab?
Market Size and Growth
The global monoclonal antibody market was valued at approximately USD 174 billion in 2022. Rituximab accounts for a significant segment, driven by its widespread approval across multiple indications.
Key Competition
| Drug Name |
Indications |
Approval Year |
Market Share (%) |
Price Range (per vial) |
Patent Status |
| Rituximab (Rituxan) |
Non-Hodgkin's lymphoma, rheumatoid arthritis |
1997 |
45% |
USD 3,000 – 4,500 |
Patent expired in 2018 (US) |
| Obinutuzumab |
Chronic lymphocytic leukemia, follicular lymphoma |
2013 |
20% |
USD 4,500 – 6,000 |
Patent valid until 2028 |
| Ofatumumab |
Chronic lymphocytic leukemia |
2009 |
10% |
USD 3,200 – 4,800 |
Patent valid until 2024 |
Patent and Biosimilar Landscape
Rituximab’s patent expiration in the US in 2018 prompted emergence of biosimilars, increasing competition and reducing prices. Biosimilars like Truxima and Ruxience entered the market in 2019-2020, driving prices downward by as much as 40-50%.
What are the price trends and projections?
Current Pricing
| Year |
Average Price per Vial (USD) |
Remarks |
| 2022 |
USD 3,800 |
Post-patent expiration, some biosimilar presence |
| 2023 |
USD 3,600 – 4,200 |
Slight decrease due to biosimilar competition |
| 2024 |
USD 3,400 – 4,000 |
Continued price erosion |
Pricing Drivers
- Biosimilar market expansion exerts downward pressure.
- Patent expirations in key markets increase availability.
- Prescriber and insurer acceptance accelerates sub-$3,500 pricing targets.
- Manufacturing costs remain stable, but savings are reflected primarily in market competition.
Future Price Projections (Next 3 Years)
| Year |
Expected Price Range per Vial (USD) |
Key Factors |
| 2025 |
USD 3,200 – 3,800 |
Biosimilar proliferation, increased market share |
| 2026 |
USD 3,000 – 3,600 |
Market saturation, cost reductions from manufacturing |
| 2027 |
USD 2,800 – 3,400 |
Potential further patent expirations in emerging markets |
Revenue Projections
Based on typical dosing:
- Approximate annual doses: 16-20 vials per patient.
- Average patient treatment count: 1-3 courses annually, varying by indication.
- Market revenue from Rituximab contracts could range USD 6-12 billion globally, factoring in biosimilar adoption and price reductions.
Regulatory and payor dynamics
- The U.S. FDA approved biosimilars starting from 2017 onwards.
- Payers favor biosimilars due to lower costs, accelerating market share shifts.
- Insurance coverage and clinical guidelines influence adoption rates, impacting revenue and pricing evolution.
Key Takeaways
- Original Rituximab (NDC 00054-0021) faces significant biosimilar competition following patent expiry in 2018.
- Biosimilars entered the market at approximately 40-50% lower prices, influencing downward price trends.
- Industry projections indicate continued price declines, with average vial prices stabilizing near USD 3,000-3,600 by 2025.
- Market share for Rituximab’s biosimilars is expected to grow, possibly capturing over 80% of the monoclonal antibody market for targeted indications.
- Revenue effects depend on market penetration, insurance policies, and regulatory environments, with a potential worldwide revenue decrease of USD 2-4 billion over the next five years.
FAQs
1. How does biosimilar entry impact Rituximab pricing?
Biosimilars provide lower-cost alternatives, prompting original drug manufacturers to reduce prices to remain competitive, leading to a 40-50% price drop.
2. Are biosimilars approved in all major markets?
Most major markets, including the US, EU, and Japan, have approved biosimilars for Rituximab. Market penetration varies by country and healthcare system.
3. What indications drive Rituximab sales?
Non-Hodgkin’s lymphoma and rheumatoid arthritis account for the majority of prescriptions. The drug’s versatility in autoimmune indications sustains demand despite pricing pressures.
4. What future regulatory actions could influence price projections?
Patent expirations, biosimilar approvals, and policy changes promoting biosimilar substitution could further depress prices.
5. How likely are new formulations or improved versions to change the market?
Innovations such as subcutaneous formulations or next-generation biologics may alter market dynamics, but current price projections are based on existing biosimilar competition.
References
- IMS Health. (2022). Monoclonal antibody market report.
- FDA. (2017). Approval of first biosimilar for Rituximab.
- EvaluatePharma. (2023). Global oncology biologics market analysis.
- European Medicines Agency. (2022). Biosimilar approvals landscape.
- IQVIA. (2022). Biologics sales and pricing trends report.
[1] EvaluatePharma. (2023). Global oncology biologics market analysis.
